Bulletin
Investor Alert

New York Markets Close in:

Merck & Co. Inc.

NYS: MRK

GO
/marketstate/country/us

Market open

 --Real time quotes

Feb 25, 2021, 12:22 p.m.

MRK
/zigman2/quotes/209956077/composite

$

74.59

Change

+0.02 +0.02%

Volume

Volume 4.08m

Real time quotes

/zigman2/quotes/209956077/composite

Previous close

$ 74.57

$ 74.59

Change

+0.02 +0.02%

Day low

Day high

$74.08

$75.00

Open

52 week low

52 week high

$65.25

$87.80

Open

Company Description

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutica...

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Valuation

P/E Current

26.81

P/E Ratio (with extraordinary items)

26.80

P/E Ratio (without extraordinary items)

29.41

Price to Sales Ratio

4.33

Efficiency

Profitability

Gross Margin

73.76

Operating Margin

25.92

Pretax Margin

18.32

Net Margin

14.72

Capital Structure

Officers and Executives

Name Age Officer Since Title
Mr. Kenneth C. Frazier 64 1992 Chairman, President & Chief Executive Officer
Mr. Robert M. Davis 53 2014 Chief Financial Officer & Executive Vice President
Ms. Sandy Tremps - 1988 Vice President-R&D IT CIO
Dr. Chia Lin Wang - - CEO-Development Centre
Mr. Sanat Chattopadhyay - - EVP & President-Merck Manufacturing Division

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/09/2020 Kenneth C. Frazier
Chairman, President & CEO; Director
144,866   Disposition at $81.74 per share. 11,841,346
11/09/2020 Kenneth C. Frazier
Chairman, President & CEO; Director
135,134   Disposition at $81.08 per share. 10,956,664
10/30/2020 Kenneth C. Frazier
Chairman, President & CEO; Director
64,073   Gift at $0 per share. 0
10/30/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
1,137   Derivative/Non-derivative trans. at $75.89 per share. 86,286
10/30/2020 Michael T. Nally
EVP, Chief Marketing Officer
995   Derivative/Non-derivative trans. at $75.89 per share. 75,510
10/30/2020 Steven C. Mizell
EVP, Chief HR Officer
2,273   Derivative/Non-derivative trans. at $75.89 per share. 172,497
10/30/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
2,287   Derivative/Non-derivative trans. at $75.89 per share. 173,560
10/30/2020 Michael T. Nally
EVP, Chief Marketing Officer
2,287   Derivative/Non-derivative trans. at $75.89 per share. 173,560
10/30/2020 Steven C. Mizell
EVP, Chief HR Officer
4,574   Derivative/Non-derivative trans. at $75.89 per share. 347,120
10/05/2020 Robert M. Davis
EVP, Global Svcs & CFO
251,273   Disposition at $81.03 per share. 20,360,651
10/05/2020 Robert M. Davis
EVP, Global Svcs & CFO
251,273   Derivative/Non-derivative trans. at $0 per share. 0
09/17/2020 Kenneth C. Frazier
Chairman, President & CEO; Director
15,500   Gift at $0 per share. 0
08/25/2020 Kenneth C. Frazier
Chairman, President & CEO; Director
12,500   Gift at $0 per share. 0
08/13/2020 Sanat Chattopadhyay
Exe V-P & Pres. MMD
10,380   Disposition at $83.01 per share. 861,643
08/05/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
18,876   Disposition at $81.55 per share. 1,539,337
08/05/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
18,876   Derivative/Non-derivative trans. at $0 per share. 0
07/17/2020 Julie Louise Gerberding
EVP Strat Comm, GI Pub Policy
18,174   Disposition at $80.01 per share. 1,454,101
07/17/2020 Julie Louise Gerberding
EVP Strat Comm, GI Pub Policy
18,111   Disposition at $80 per share. 1,448,880
07/17/2020 Julie Louise Gerberding
EVP Strat Comm, GI Pub Policy
18,111   Derivative/Non-derivative trans. at $0 per share. 0
05/07/2020 Leslie A. Brun
Director
5,000   Disposition at $75.46 per share. 377,300
05/07/2020 Wendell P. Weeks
Director
5,000   Disposition at $76.02 per share. 380,100
05/07/2020 Leslie A. Brun
Director
5,000   Derivative/Non-derivative trans. at $0 per share. 0
05/07/2020 Wendell P. Weeks
Director
5,000   Derivative/Non-derivative trans. at $0 per share. 0
05/05/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
1,848   Derivative/Non-derivative trans. at $76.86 per share. 142,037
05/05/2020 Rita A. Karachun
Sr. VP Fince-Global Controller
1,617   Derivative/Non-derivative trans. at $76.86 per share. 124,282
05/05/2020 Michael T. Nally
EVP, Chief Marketing Officer
1,020   Derivative/Non-derivative trans. at $76.86 per share. 78,397
05/05/2020 Michael Fleming
SVP Chief Ethics & Com Officer
458   Derivative/Non-derivative trans. at $76.86 per share. 35,201
05/05/2020 Frank K. Clyburn
EVP, Chief Commercial Officer
3,752   Derivative/Non-derivative trans. at $76.86 per share. 288,378
05/05/2020 Rita A. Karachun
Sr. VP Fince-Global Controller
3,283   Derivative/Non-derivative trans. at $76.86 per share. 252,331
05/05/2020 Michael T. Nally
EVP, Chief Marketing Officer
2,345   Derivative/Non-derivative trans. at $76.86 per share. 180,236
05/05/2020 Michael Fleming
SVP Chief Ethics & Com Officer
1,290   Derivative/Non-derivative trans. at $76.86 per share. 99,149
/news/latest/company/us/mrk

MarketWatch News on MRK

  1. Merck Pays Double to Buy Pandion Therapeutics

    10:50 a.m. Today

    - Josh Nathan-Kazis

  2. Merck to buy Pandion Therapeutics for 134% premium

    6:57 a.m. Today

    - Tomi Kilgore

  3. Merck to pay $60/share in cash for each Pandion share, a 134.1% premium

    6:50 a.m. Today

    - Tomi Kilgore

  4. Merck to buy Pandion Therapeutics in a deal valued at $1.85 bln

    6:49 a.m. Today

    - Tomi Kilgore

  5. Pfizer Inc. stock underperforms Wednesday when compared to competitors

    5:08 p.m. Feb. 24, 2021

    - MarketWatch Automation

  6. Pfizer Inc. stock falls Tuesday, underperforms market

    5:07 p.m. Feb. 23, 2021

    - MarketWatch Automation

  7. Pfizer Inc. stock outperforms market despite losses on the day

    5:07 p.m. Feb. 22, 2021

    - MarketWatch Automation

  8. Blackstone Makes a Big Bet on Life Sciences

    5:32 p.m. Feb. 19, 2021

    - Liz Moyer

  9. Pfizer Inc. stock falls Friday, underperforms market

    5:08 p.m. Feb. 19, 2021

    - MarketWatch Automation

  10. Pfizer Inc. stock falls Thursday, underperforms market

    5:07 p.m. Feb. 18, 2021

    - MarketWatch Automation

  11. Pfizer Inc. stock rises Wednesday, outperforms market

    5:08 p.m. Feb. 17, 2021

    - MarketWatch Automation

  12. 5 Affordable Biopharma Stocks With Growth Potential

    12:06 p.m. Feb. 17, 2021

    - Josh Nathan-Kazis

  13. Bitcoin’s Run Doesn’t Make Sense

    8:20 a.m. Feb. 17, 2021

  14. Pfizer Inc. stock falls Tuesday, underperforms market

    5:08 p.m. Feb. 16, 2021

    - MarketWatch Automation

  15. Berkshire Hathaway ups drug-stock stakes while trimming Apple

    4:44 p.m. Feb. 16, 2021

    - Wallace Witkowski

  16. Berkshire Hathaway ups drug-stock stakes while trimming Apple

    4:44 p.m. Feb. 16, 2021

    - Wallace Witkowski

  17. Loading more headlines...
/news/nonmarketwatch/company/us/mrk

Other News on MRK

  1. PAND Stock: Why Pandion Therapeutics Shares Have Skyrocketed Today

    10:16 a.m. Today

    - InvestorPlace.com

  2. Merck to acquire Pandion in a deal valued at $2 billion

    7:09 a.m. Today

    - Seeking Alpha

  3. 10-K: NOVOCURE LTD

    6:30 a.m. Today

    - Edgar Online - (EDG = 10Q, 10K)

  4. Big Pharma Short Percentage Is Below Overall Market

    4:18 p.m. Feb. 23, 2021

    - GuruFocus.com

  5. Novavax Nears Covid-19 Vaccine Game Changer—After Years of Failure

    11:09 a.m. Feb. 23, 2021

    - Gregory Zuckerman

  6. To Make More Covid-19 Vaccines, Rival Drugmakers Team Up

    7:00 a.m. Feb. 23, 2021

    - Jared S. Hopkins

  7. To Make More Covid-19 Vaccines, Rival Drugmakers Team Up

    7:00 a.m. Feb. 23, 2021

    - Jared S. Hopkins

  8. What’s Keeping Black Workers From Moving Up the Corporate Ladder?

    12:00 p.m. Feb. 21, 2021

    - Vanessa Fuhrmans

  9. Why Piotroski's F-Score No Longer Works

    10:10 a.m. Feb. 20, 2021

    - Seeking Alpha

  10. Prem Watsa's Top 5 Trades of the 4th Quarter

    4:27 p.m. Feb. 18, 2021

    - GuruFocus.com

  11. Loading more headlines...

At a Glance

Merck & Co., Inc.

2000 Galloping Hill Road

Kenilworth, New Jersey 07033

Phone

1 9087404000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$47.99B

Net Income

$7.07B

2020 Sales Growth

3.0%

Employees

-

/news/pressrelease/company/us/mrk

Press Releases on MRK

  1. Global Protein Assays Market: Impact of COVID-19

    36 min ago

    - Heraldkeepers

  2. Pharmaceuticals for Women’s Health: Global Markets

    57 min ago

    - Heraldkeepers

  3. Anti-Infective Drugs Global Market Report 2021: COVID 19 Implications and Growth to 2030

    11:06 a.m. Today

    - GlobeNewswire

  4. Health Technology Assessment in Pharma: A Review of Major Decisions

    8:25 a.m. Today

    - Heraldkeepers

  5. Medisafe Secures $30M in Series C Funding to Build Future Model of Patient Support

    8:01 a.m. Today

    - PR Newswire - PRF

  6. Loading more headlines...
Link to MarketWatch's Slice.